Mimetogen Pharmaceuticals - Company & Market Research Reports

Mimetogen Pharmaceuticals is a biotechnology company that develops the use of peptidomimetics to treat ophthalmic diseases with high unmet medical needs. MIM-D3 is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. In addition, Mimetogen has developed novel therapeutic approaches or other ophthalmology indications, including glaucoma and other degenerative diseases of the retina. The company was founded in 2004 and is based in Montreal, Canada.

From
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
  • 5 Results (Page 1 of 1)
Loading Indicator
adroll